IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
IN8bio (NASDAQ:INAB) & Cadrenal Therapeutics (NASDAQ:CVKD) Head to Head Review
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio to Present at Upcoming Investor Conferences